title: Effect of carnosine, aminoguanidine, and aspirin drops on the prevention of cataracts in diabetic rats.
abstract: OBJECTIVE
  To investigate the effect of carnosine (CA), aminoguanidine (AG), and aspirin (ASA) drops, all inhibitors of glycation, on the development of diabetic cataract in rat.
  
  
  METHODS
  Rats were made diabetic with streptozotocin, and based on the level of plasma glucose, they were assigned as non-diabetic rats (<14 mmol/l plasma glucose) and diabetic rats (>14 mmol/l plasma glucose). Animals in the treated groups received CA, AG, and ASA as drops to the left eyes starting from the day of streptozotocin injection. Progression of lens opacification was recorded using the slit lamp at regular time intervals. All the rats were killed after the week 13, and the levels of advanced glycation end products (AGE), glutathione reductase (GR), catalase (CAT), and glutathione (GSH) were determined.
  
  
  RESULTS
  Lens opacification progressed in a biphasic manner in the diabetic rats, an initial slow increase during the first eight weeks of diabetes followed by a steep increase in the next five weeks. Carnosine treatment delayed the progression of cataracts in diabetic rats, and the delay was statistically significant on the fourth week of diabetes (p<0.05, when compared with untreated moderately diabetic rats). A decrease in the antioxidant enzymes of CAT and the level of GSH was found in the lens of the untreated diabetic rats at 13 weeks after injection. Some protection was provided in the treated eyes. The level of glycation in the untreated diabetic rats was significantly higher than that in the normal rats (p<0.001). After treatment with CA, AG, and ASA, those diabetic rats had a lower level of glycated lens protein compared to the untreated diabetic rats (p<0.001).
  
  
  CONCLUSIONS
  These results thus suggest that the effect of CA, AG, and ASA is indeed inhibition of the formation of AGEs. However, the effect of CA, AG, and ASA is overwhelmed by the excessive accumulation of AGEs in the severely diabetic rats. CA compared with AG and ASA treatment can delay the progression of lens opacification in the diabetic rats only during the earlier stages. It also protects against the inactivation of enzymes.
authors.affiliation: Department of Ophthalmology, Tangdu Hospital, Fourth Military Medical University, Xi'an, China. yhongb@fmmu.edu.cn
authors.forename: Hong
authors.initials: H
authors.lastname: Yan
authors.forename: Yong
authors.initials: Y
authors.lastname: Guo
authors.forename: Jie
authors.initials: J
authors.lastname: Zhang
authors.forename: Zhenghua
authors.initials: Z
authors.lastname: Ding
authors.forename: Wenjing
authors.initials: W
authors.lastname: Ha
authors.forename: J J
authors.initials: JJ
authors.lastname: Harding
mesh_terms: D000818:Animals; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D002336:Carnosine / Q000494:pharmacology / Q000627:therapeutic use*; D002386:Cataract / Q000150:complications* / Q000473:pathology / Q000517:prevention & control*; D003315:Cornea / Q000187:drug effects / Q000473:pathology; D003921:Diabetes Mellitus, Experimental / Q000150:complications* / Q000473:pathology; D018450:Disease Progression; D005136:Eye Proteins / Q000378:metabolism; D006031:Glycosylation / Q000187:drug effects; D006146:Guanidines / Q000494:pharmacology / Q000627:therapeutic use*; D007908:Lens, Crystalline / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D008297:Male; D009883:Ophthalmic Solutions; D051381:Rats; D017207:Rats, Sprague-Dawley; D013194:Staining and Labeling; D013311:Streptozocin
chemical_list: D001786:Blood Glucose; D005136:Eye Proteins; D006146:Guanidines; D009883:Ophthalmic Solutions; D013311:Streptozocin; D002336:Carnosine; D001241:Aspirin; C004479:pimagedine